To evaluate the safety, tolerability and pharmacokinetics of ABT-072 in healthy volunteers and its anti-viral activity in HCV infected subjects.
No linked publications found in PubMed
Inclusion Criteria: Criteria for Healthy Adults: * Informed consent has been obtained * Subject is in general good health * If female, then postmenopausal * If female, then not pregnant * If male, must be surgically sterile or both he and the partner must use birth control * Body Mass Index is 18 to 29, inclusive Criteria for HCV-infected Adults: * Infected with HCV for at least 6 months as shown by either detectable HCV RNA or reactive antibody, or liver biopsy with pathology indicative of HCV infection, or disclosure of a risk factor * Subject is infected with HCV genotype 1 with detectable HCV RNA of \> 50,000 IU/mL Exclusion Criteria: Criteria for Healthy Adults: * If female, then pregnant or breast feeding * Positive HAV-IgM, HBs-Ag, HCV Ab or HIV Ab * Within 6 months of start of study, drug or alcohol abuse and use of nicotine products * Alcohol intake within 48 hours prior to study drug administration Criteria for HCV-infected Adults: * Need for prescription or over-the-counter medication * Child Pugh score \> 5 or clinical evidence of cirrhosis * No other cause for liver disease other than HCV infection * ALT or AST \> 4 x ULN * Creatinine \> ULN * Clinically significant abnormal ECG * HCV RNA levels above the level of assay quantification * TSH values outside normal range